Effects of Chitin-Glucan on Oxidized Low-Density Lipoprotein (LDL)

Completed · Not applicable · Has a placebo group

Conditions studied: Cardiovascular

In brief

Cardiovascular diseases (CVDs), especially atherosclerotic coronary heart disease and stroke, are the leading causes of death globally. Important risk factors for CVDs include elevated serum levels of total cholesterol, low-density lipoprotein(LDL)-cholesterol, triglycerides, and low high-density lipoprotein (HDL)-cholesterol. Elevated "oxidized" LDL, a pro-inflammatory villain, has also emerged as an important risk factor for the development of CVDs. There is a growing need to identify safe and effective nutritional interventions that offer a clinical benefit aimed at reducing one more of the risk factors for CVDs. Data from many studies in humans have shown various health benefits provided by dietary fiber intake, including an inverse association with the risk of developing cardiovascular disease. The primary purpose of this study is to determine whether daily consumption for 6 weeks of chitin-glucan, a fiber purified from a microorganism, is effective at reducing the amount of oxidized LDL in humans with borderline-to-high LDL-cholesterol. The effects of chitin-glucan on other cardiovascular risk factors will also be evaluated.

Key facts

Study ID

NCT01232309

Run by

Stratum Nutrition

People needed

135

Starts

2010-08-01

Expected to finish

2011-01-01

Last updated by the study team

2012-10-23

Who can join

Age: 21 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female able to read, comprehend, and write English at sufficient level to complete study-related materials including informed consent
• Age: 21 - 70 years
• Body Mass Index: 18.5 - 34.9 kg/m2
• Fasting serum LDL-cholesterol: ≥ 130 - 189.9 mg/dl
• Willing to take supplement three times daily for 6 weeks and undergo other study-related procedures
• Is otherwise is in general good health as determined by the principal investigator

You may not qualify if…

• Known hypersensitivity or intolerance to fiber or fiber-containing products
• Use of any investigational drugs prior to Visit 1
• Participation in any clinical trial while participating in this trial
• Member or family member of research staff or study sponsor involved in the conduct of this trial
• Greater than 5% change in body weight within 1 month of Visit 1
• Positive pregnancy test
• Is taking lipid-altering drug therapy within four weeks prior to Visit 1. Also excluded are supplements known to have significant lipid altering effects, such as niacin (>100 mg per day), garlic (> 600 mg per day), omega-3 fatty acids (> 1 g omega-3 fatty acids per day), red yeast rice extract, phytostanols / phytosterols (> 0.5 g per day), soluble fiber (>1 g per day), chitosan (> 1 g per day) and conjugated linoleic acid (CLA; > 3 g per day)
• Excluded concurrent medications are: systemic corticosteroids (nasal and inhaled corticosteroids are permitted), orlistat, bile acid resins, no more than 1 g of prescription omega-3 fatty acids, cyclical or non-continuous hormone therapy (estrogen or testosterone)
• No more than 2 units of ethanol per day. Units are defined as 1.5 ounces of 80 proof alcohol per day, e.g. 2 twelve ounce cans of beer per day.
• Has a fasting serum triglyceride > 300 mg/dl
• Has a diagnosis of type 1 or type 2 diabetes mellitus or fasting glucose > 126 mg/dl
• Has a serum thyroid-stimulating hormone (TSH) higher than 1.5 times the upper limit of normal for the laboratory
• Is breast feeding, pregnant, or planning on becoming pregnant during the duration of the study
• Known cardiovascular disease or stroke, except for conditions that are deemed clinically insignificant by Principle Investigator or Sub-investigator, or study site physician (e.g. clinically insignificant atherosclerotic lesions observed by imaging studies).
• History of significant gastrointestinal disease such as severe constipation, diarrhea, malabsorptive disease, inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis)
• History of severe psychiatric illness which in the opinion of the investigator would interfere with the optimal participation in the study
• History if cancer within 5 years of Visit 1 (except for successfully treated basal and squamous cell carcinoma of the skin)
• Known human immunodeficiency virus (HIV) seropositivity
• History of bariatric surgery
• Aspartate aminotransferase (AST) or alanine transaminase (ALT) > 3 times the upper limit of normal
• Creatine kinase (CK) ≥ 3 times the upper limit of normal, unless explained by recent physical activity or trauma; or > 5 times the upper limit of normal, irrespective of circumstance
• Creatinine ≥ 1.5 mg/dl
• Individuals who in the opinion of the principal investigator have a risk of non-compliance to the study procedures or who are otherwise not appropriate to include in this clinical trail

Where it is running

• Provident Clinical Research and Consulting — Addison, Illinois, United States
• Louisville Metabolic and Atherosclerosis Research Center (L-MARC) — Louisville, Kentucky, United States
• KGK Synergize — London, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.